Loading…
Cell Point (India) (CELLPOINT)₹15.90+8.53%Speciality Retail
In the Mar 2026 quarter (standalone), Cell Point (India) reported sales of ₹190 Cr, up 11.7% from Mar 2025, and net profit of ₹0 Cr, down 100.0% year on year. For the year to Mar 2026, sales were ₹367 Cr and net profit ₹0 Cr.
Company filings, standalone accounts; latest reported quarter Mar 2026
| Mar 2023 | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 146 | 157 | 162 | 154 | 170 | 176 | 190 |
| Expenses | 138 | 153 | 160 | 150 | 169 | 174 | 186 |
| Operating Profit | 9.01 | 5.01 | 4.01 | 5.01 | 3.01 | 4.01 | 6.01 |
| OPM % | 6.0% | 2.9% | 2.5% | 3.0% | 1.6% | 2.4% | 3.1% |
| Other Income | 1.01 | 2.01 | 0.00 | 1.01 | 3.01 | 0.00 | 0.00 |
| Interest | 5.01 | 3.01 | 2.01 | 2.01 | 3.01 | 2.99 | 3.99 |
| Depreciation | 1.01 | 0.00 | 2.01 | 3.01 | 0.00 | 1.01 | 2.01 |
| Profit before tax | 3.98 | 1.99 | 0.00 | 0.00 | 1.99 | 0.00 | 0.99 |
| Tax % | 37.0% | 28.0% | 100.0% | 28.0% | 18.0% | 26.0% | 119.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 1.38 | 0.00 | 0.00 |
| Net Profit | 2.99 | 1.99 | 0.00 | 0.00 | 1.99 | 0.00 | 0.00 |
| EPS (Rs) | 2.06 | 0.89 | 0.00 | 0.11 | 1.08 | 0.09 | −0.06 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 269 | 218 | 259 | 285 | 309 | 308 | 367 |
| Expenses | 262 | 212 | 250 | 269 | 302 | 303 | 359 |
| Operating Profit | 9.02 | 8.01 | 11.02 | 18.01 | 9.01 | 7.01 | 10.02 |
| OPM % | 3.5% | 3.6% | 4.2% | 6.0% | 2.8% | 2.4% | 2.8% |
| Other Income | 1.01 | 1.01 | 1.01 | 1.01 | 2.01 | 4.01 | 1.01 |
| Interest | 5.99 | 5.99 | 8.01 | 9.01 | 6.01 | 5.01 | 5.99 |
| Depreciation | 2.01 | 1.01 | 1.01 | 1.01 | 2.01 | 3.01 | 3.01 |
| Profit before tax | 1.99 | 0.99 | 1.99 | 9.96 | 2.99 | 2.99 | 0.99 |
| Tax % | 33.0% | 46.0% | 32.0% | 32.0% | 38.0% | 20.0% | 94.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.99 | 0.00 |
| Net Profit | 1.99 | 0.99 | 1.99 | 6.99 | 1.99 | 1.99 | 0.00 |
| EPS (Rs) | 14.00 | 6.04 | 14.45 | 4.91 | 0.89 | 1.20 | 0.02 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 28.0% | 0.0% | 0.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.99 | 0.99 | 0.99 | 13.97 | 18.98 | 18.98 | 18.96 |
| Reserves | 9.98 | 10.97 | 11.97 | 5.98 | 52.85 | 55.87 | 55.86 |
| Borrowings | 29.10 | 39.09 | 52.14 | 56.14 | 49.19 | 45.15 | 77.17 |
| Other Liabilities | 15.92 | 14.93 | 17.91 | 18.91 | 13.02 | 18.98 | 17.91 |
| Total Liabilities | 55.99 | 64.98 | 83.01 | 95.00 | 134 | 138 | 169 |
| Fixed Assets | 18.95 | 18.93 | 18.93 | 17.95 | 32.92 | 36.88 | 59.85 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 36.04 | 46.05 | 64.08 | 76.05 | 101 | 101 | 109 |
| Inventories | 19.97 | 25.94 | 37.90 | 45.89 | 54.87 | 63.86 | 65.93 |
| Trade receivables | 0.99 | 0.00 | 0.00 | 0.00 | 0.00 | 0.99 | 0.99 |
| Cash & equivalents | 2.99 | 2.99 | 7.98 | 9.97 | 11.95 | 5.98 | 5.98 |
| Total Assets | 55.99 | 64.98 | 83.01 | 95.00 | 134 | 138 | 169 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 0.99 | 1.99 | 0.00 | 6.01 | −6.99 | −0.99 | 0.99 |
| Cash from investing activity | −0.99 | −0.99 | 0.00 | −2.99 | −30.90 | 1.99 | −27.90 |
| Cash from financing activity | 0.99 | 0.00 | 4.99 | −0.99 | 38.93 | −6.98 | 25.95 |
| Net cash flow | 0.99 | 1.01 | 4.99 | 2.01 | 1.99 | −5.99 | −0.99 |
| Capex | 1.02 | 1.15 | 0.45 | 0.44 | 16.89 | 4.99 | 26.38 |
| Free cash flow | 0.00 | 0.99 | −0.99 | 5.99 | −23.99 | −5.99 | −24.97 |
| CFO / OP % | 26.1% | 39.1% | 5.0% | 42.1% | −61.9% | −8.9% | 19.1% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 1 | 0 | 1 | 0 | 0 | 1 | 1 |
| Inventory days | 32 | 51 | 64 | 71 | 76 | 87 | 79 |
| Days payable | 18 | 18 | 20 | 17 | 11 | 18 | 15 |
| Cash conversion cycle | 13 | 31 | 42 | 53 | 63 | 68 | 63 |
| Working capital days | 6 | −3 | −11 | −9 | −3 | 11 | 16 |
| ROCE % | — | 16.0% | 18.0% | 26.0% | 9.0% | 5.0% | 5.0% |
For the Mar 2026 quarter, Cell Point (India) reported sales of ₹190 Cr, up 11.7% year on year and net profit of ₹0 Cr, down 100.0% year on year. The operating margin was 3.1%.
Cell Point (India)'s sales for the year to Mar 2026 were ₹367 Cr.
Net profit for the year to Mar 2026 was ₹0 Cr. Earnings per share over the same trailing period were ₹0.02.
Cell Point (India) reported borrowings of ₹77.17 Cr at Mar 2026, against cash and equivalents of ₹5.98 Cr.
Cash from operations was ₹0.99 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹24.97 Cr.